First Anti-bacterial Enzyme Against MRSA for Use in Humans

08/11/2014 - 3 minutes

Change the way we fight against bacterial infections: MICREOS launches its first anti-bacterial enzyme for use in humans against MRSA (Methicillin-resistant Staphylococcus aureus).

Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA).

Emergence of endolysin resistance is not expected and beneficial bacteria are left unharmed by this possible treatment based on the Endolysine Staphefekt ™

Staphefekt™ is the first endolysin available for human use, on intact skin. Endolysins are enzymes that comes from bacteriophages (or phages), microorganisms that kill only bacteria. In nature, phages use bacteria to replicate, in the process destroying the bacterial cell wall with endolysins. The working mechanism of endolysins is unrelated to that of antibiotics, meaning even bacteria resistant to antibiotics are susceptible. Staphefekt™ exhibits several other characteristics: rapid killing (lysis) of the target bacteria and very limited likelihood of emerging resistance, as it works independent of the bacterial metabolism – which harbours the resistance mechanisms –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member